CME Nuclear medicine (108462): self-assessment questionnaire
SAQs and answers are ONLINE for RCP fellows and collegiate members
SAQs and answers are ONLINE for RCP fellows and collegiate members
Format
Candidates are asked to choose the best answer from the five possible answers. This best of five format is used in many medical examinations, however the questions are not intended to be representative of those used in the MRCP(UK) Part 1 or Part 2 Written Examinations.
The answering process
Go to www.rcplondon.ac.uk/SAQ
Log on using your usual RCP username and password
Select the relevant CME question paper
Answer all 10 questions by selecting the best answer from the options provided
Once you have answered all the questions, click on Submit
Registering your external CPD credits
Carrying out this activity allows you to claim two external CPD credits. These will be automatically transferred to your CPD diary, where you can review the activity and claim your points.
Positron emission tomography/computerised tomography
can be used for detecting the source of sepsis in problematic cases and in pyrexia of unknown origin
imaging with amyloid tracers is specific for Alzheimer’s disease
is not currently funded for non-oncological indications in the UK
should be reserved only for the assessment of high-risk solitary pulmonary nodules
uses fludeoxyglucose as a universal imaging agent for all types of cancer.
Contrast agents for use in combined modality imaging
can provide images at both whole body and cellular level if they incorporate optical contrast
cannot be used in conjunction with single-photon emission computerised tomography imaging
confer the advantage of lower absorbed radiation dose compared with conventional imaging
must contain a radionuclide for use during surgery
must contain more than one type of contrast in a single entity to be useful.
Which radiopharmaceutical has demonstrated survival benefit in patients with bone metastases from prostate cancer?
Iodine-131
Radium-223
Strontium-89
Samarium-153
Technetium-99m.
Which of these is the most common organ for metastases from castration-resistant prostate cancer?
bone
brain
liver
lung
spleen.
Which of the following is true regarding peptide receptor radionuclide therapy (PRRT)?
The most commonly used PRRT agent is 90Y-DOTATATE.
PRRT is indicated as first-line therapy for patients with grade 2 neuroendocrine tumours.
Renal impairment is more likely to occur following 90Y-DOTATATE rather than 177Lu-DOTATATE.
Renal toxicity is the most common side effect.
Somatostatin receptor uptake scan is not required for selection for PRRT.
Which of the following is true regarding meta-iodobenzylguanidine (MIBG)?
123I-MIBG is the functional imaging agent of choice in the majority of neuroendocrine tumours.
MIBG is a catecholamine analogue.
MIBG is taken up and stored in the cytoplasm of the tumour cells.
MIBG therapy is performed using 123I-MIBG.
The target is the somatostatin receptor.
131I-radioiodine is used in the treatment of benign and malignant thyroid disease because of its
alpha-particle emission
beta- and alpha-particle emission
beta-particle emission
gamma ray emission
positron emission.
In benign thyroid disease, 131I-radioiodine is indicated in the treatment of
De Quervains thyroiditis
differentiated thyroid cancer
Graves’ disease
Hashimoto’s thyrotoxicosis
hyperthyroidism due to any cause.
An advantage of yttrium-90 as a radionuclide for selective internal radiation therapy is that
it has a long physical half-life
it emits easy to image gamma rays
it emits short-range beta radiation, resulting in cell damage
it is excreted via the faeces
it is cheap.
The first angiogram for selective internal radiation therapy is required to
identify the liver arterial anatomy
embolise the gastroduodenal artery, if necessary
administer technetium-99m macroaggregated albumin and determine the lung shunt fraction
all of the above
none of the above.
CME Geriatric medicine SAQ
Answers to the CME SAQ published in Clinical Medicine in August 2017
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10
(c) (e) (d) (e) (d) (c) (a) (d) (d) (c)
- © Royal College of Physicians 2017. All rights reserved.
Article Tools
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.